Frazier Life Sciences announced the closing of a $987 million funding for biopharmaceuticals, focusing on company creation and early-stage venture funding, along with 80% set aside for private companies.
The healthcare venture capital company is based in Seattle and Menlo Park, California and recently led a $91 million private placement funding round for Seattle’s Alpine Immune Sciences to support clinical trials. They also invested in cell therapy company Sonoma Biotherapeutics, which has laboratory space in Seattle.
“Between [Frazier’s VC funds] FLS XI and FLSPF, we have over $1.8 billion of active funds to support biopharmaceutical companies at all stages of growth, from company formation through public offerings,” said James Topper, managing partner at Frazier Life Sciences.